Absence of the CHEK2 c.1100delC mutation in familial breast and ovarian cancer in Colombia: a case-control study [version 1; peer review: 2 approved with reservations]

Ana-Lucia Rivera-Herrera¹, Laura Cifuentes-C², JA Gil-Vera¹, Guillermo Barreto¹

¹Human Molecular Genetics Lab, Biology Department, Universidad del Valle, Calle 13 No. 100-00, A.A.25360, Cali, Colombia
²GIOD group, Universidad Cooperativa de Colombia, Calle 18 No. 47–150, A.A.520002, Pasto, Colombia

Abstract
Background: BRCA1 and BRCA2 have been identified as high-penetrance breast cancer predisposition genes, but they only account for a small fraction of the inherited component of breast cancer. To explain the remaining cases, a polygenic model with a large number of low- to moderate-penetration genes have been proposed; one of these, is the CHEK2 gene (Checkpoint Kinase 2). The objective of this study was to determine the role of the CHEK2 gene, specifically the c.1100delC mutation in familial breast cancer susceptibility in Colombian patients.
Methods: We screened 131 high-risk breast and/or ovarian cancer patients (negative for mutations in BRCA1 and BRCA2) and 131 controls for the germline mutation CHEK2 c.1100delC by allele-specific PCR.
Results: None of the cases or controls showed the CHEK2 c.1100delC mutation, neither as a homozygote nor as a heterozygote.
Conclusions: Our results suggest that the CHEK2 c.1100delC mutation is not a risk factor for genetic susceptibility to familial breast or ovarian cancer in the Colombian population. The absence of the CHEK2 c.1100delC mutation in our population show the importance of considering ethnic background before offering a genetic test.

Keywords
CHEK2, familial breast and ovarian cancer, Colombia, CHEK2 c.1100delC, moderate-penetrance
Introduction

Breast cancer (BC) is the most common type of cancer among women¹, and in Colombia, it is the main cause of death by cancer in women*. Of all cases of BC, approximately 5–10% have a strong inherited component, of which 25% is explained by germline mutations in the genes BRCA1 and BRCA2.⁵ To explain the BRCA1/2-negative cases, a polygenic model in which a large number of low- to moderate-penetrance genes as collectively responsible for the disease has been proposed⁶⁻⁷.

CHEK2 has been proposed as a moderate penetrance BC susceptibility gene⁴. This gene controls cell cycle and apoptosis and is activated in response to DNA double-strand breakage⁸. Several mutations in the CHEK2 gene have been found, being the CHEK2 c.1100delC mutation the most studied; this is a truncating mutation in exon 10 that abolishes kinase activity of the protein⁹. The role of this mutation in breast cancer was confirmed by Meijers-Heijboer et al., and in several other studies¹⁰⁻¹². The mutation CHEK2 c.1100delC was identified in approximately 5% of families with BC that did not have mutations in either BRCA1 or BRCA2 and was estimated to confer moderate risk (20–25%) of developing breast cancer for female mutation carriers¹³.

Data on the contribution of moderate- or low-penetrance alleles to BC in South American populations are scarce. In this study, using a case-control design, we studied the CHEK2 c.1100delC mutation in order to investigate the potential influence of this variant on familial Breast and Ovarian Cancer (BOC) susceptibility in a Colombian cohort.

Materials and Methods

This was a case-control study conducted from 2009 to 2013 with 131 cases and 131 controls, which was carried out to determine the association between the CHEK2 c.1100delC mutation and increased risk of developing breast cancer. This study was approved by the Ethical Board of the School of Medicine of the University of Valle. Informed consent was obtained from all the participants.

Population Study

Cases

Our study cohort was composed of 131 Colombian familial breast/ovarian cancer (BOC) cases (BRCA1/BRCA2 negative). The patients were selected from the files of different health/Cancer centers after obtaining permission from each Center to participate in this study. These centers were located in the cities of Cali (Hospital Universitario del Valle, FUNCANCER, Clínica Rafael Uribe Uribe, Hematooncologos), Armenia (Oncólogos de Occidente), Cartagena (Fundación Hospital Infantil Napoleón Franco Pareja, Fundación mujeres por tus senos) and Bucaramanga (Insuasty Oncologia e Investigación). The selected cases met, at least, one of the following criteria: at least three family members with breast or ovarian cancer at any age; two first degree family members affected, at least one, with breast cancer before 41 years of age or with ovarian cancer at any age; one breast cancer case diagnosed before 35 years or less; one ovarian cancer case diagnosed before age 31. For all index cases, breast and ovarian cancers were verified by the original pathology report. After the selection of the patients based in the inclusion criteria (Dataset 1), they were asked to give a blood sample collected by a nurse or technician from each health/Cancer center and then sent to our laboratory.

Controls

The sample of healthy Colombian controls (n=131) consisted of unrelated individuals, with no personal or familial history of cancer, these individuals were interviewed and informed as to the aims of the study and who gave their informed written consent for anonymous testing. This control cohort was recruited in the same cities where the study cases were collected and also matched by age, sex and socioeconomic strata.

Genotyping

Genomic DNA was extracted from the blood samples of 131 the BC cases and the 131 healthy controls, for both groups the blood samples were collected specifically for this study. Samples were analyzed using allele-specific PCR (ASPCR) to detect the presence of CHEK2 c.1100delC, using the primers reported by Rashid et al.¹⁴. The products of the ASPCR were visualized by electrophoresis on an 8% polyacrylamide gel. The expected results were a band of 200 base pairs (bp) for the deletion of cytosine 1100 or a band 534 bp when the deletion is not present; if the sample showed both bands, it meant the presence of a heterozygote.

Results

A total of 262 samples (131 study cases and 131 matched-controls) were analyzed for the presence of the CHEK2 c.1100delC mutation. The clinical characteristics of the families included in this study are listed in Table 1 (Also see Dataset 1). After allele-specific PCR analysis, none of the cases or controls showed the CHEK2 c.1100delC mutation. All the samples showed only the heavier band (534bp) (Supplementary Figure 1). This indicates that the all the samples were homozygotes for the normal allele.

Discussion

This is the first study conducted in the Colombian population for CHEK2 c.1100delC mutation. Our results have shown that none of the 262 analyzed samples carried the CHEK2 c.1100delC mutation, suggesting that the frequency of this mutation is extremely low (or not present) in the Colombian population.

Similar results have been reported for populations in other South American countries. Although studies are scarce, in the few populations that have been evaluated for the presence of this variant, it has not been found in Chile¹⁶ and Mexico¹⁷, or has been found at very low frequencies in Brazilian population¹⁸⁻²⁰.

Worldwide, CHEK2 c.1100delC is absent in Spain¹⁹⁻³¹ and all Asian populations studied to date, including those in India², Japan³, China⁴, Korea⁵, Singapore⁶, the Philippines⁷, Pakistan⁸ and Malaysia⁹. The mutation is present in populations of Galicia

Dataset 1. Raw data for “Genotype and type of cancer present in the studied patients and their families”

http://dx.doi.org/10.5256/f1000research.13368.d207084
(northwest Spain) \cite{39-41}, 1.4\% of the Northern European countries including Finland, the UK and the Netherlands \cite{8,11,42} and the United States \cite{43-45}.

An explanation for this variability, proposes CHEK2 c.1100delC as an allele whose frequency is distributed along a population-gradient, which would have originated in populations of Northern Europe (with high frequencies) and decreasing towards the regions of Southern Europe (Basque Country, Spain and Italy) \cite{39}. This may explain the absence of the allele in the Colombian population, which is a mixture, in different proportions, of European-Spanish, African and Native American ancestry \cite{46}. Hence, the probability that the allele would have reached our population is low. As reported in several studies, it is evident that the contribution of CHEK2 c.1100delC mutation to the burden of cancer varies according to the ethnic group, and from country to country \cite{47}.

We found that the CHEK2 c.1100delC mutation is not present or is present at an extremely low frequency in familial BOC cases and controls in our Colombian cohort.

Based on our findings, we suggest that genotyping of the CHEK2 c.1100delC mutation in genetic testing for breast cancer susceptibility in the Colombian population should not be recommended. However, further studies are required to confirm the contribution of this variant in the Colombian population.

The study of CHEK2 mutations in the Latin American population has been focused mainly in the c.1100delC mutation. However, databases like ExAC (Exome Aggregation Consortium) showed the presence of other germline mutations in the CHEK2 gene in Latin American samples that could generate cancer susceptibility \cite{48}. Accordingly, it would be important to examine other mutations in the Colombian population and its association with the development of familial BOC.

**Data availability**

Dataset 1: Raw data for “Genotype and type of cancer present in the studied patients and their families” 10.5256/f1000research.13368.d207084

**Competing interests**

The authors declare no conflicts of interest.

**Grant information**

BG received funding by COLCIENCIAS (Grant ID 1106-519-29134) and Universidad del Valle (Grant ID CI7830).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Acknowledgments**

The authors thank the families and institutions who participated in the research studies described in this article, Hospital Universitario del Valle, FUNCANCER, Clínica Rafael Uribe Uribe, Hematooncologos, Oncólogos de Occidente, Fundación Hospital Infantil Napoleón Franco Pareja, Fundación mujeres por tus senos and Insuasty Oncologia e Investigación.

**Supplementary Material**

**Supplementary Figure 1: Allele specific PCR products for the CHEK2 c.1100delC mutation.**

Polyacrylamide gel electrophoresis at 8\% (29:1 acrylamide:bisacrylamide) of allele specific PCR products for the CHEK2 c.1100delC variant for cases and controls. Lanes 1 - 5 show the amplified product of Colombian patients with breast and/or familial ovarian cancer; lanes 7-11 show the amplified product of healthy controls; Lane 6: molecular weight marker of 100 base pairs. all individuals show an amplified product of 537 bp which corresponds to the normal genotype. The letters “p.b.” in the picture are the spanish initials for base pairs (“pares de bases”).

Click here to access the data.

PubMed Abstract | Publisher Full Text


Open Peer Review

Current Peer Review Status: ✔ ✔

Version 1

Reviewer Report 01 July 2019

https://doi.org/10.5256/f1000research.14514.r49870

© 2019 Solano A et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fernanda S. Jalil
Genotyping Section, DAC, CEMIC, Buenos Aires, Argentina

Angela R. Solano
1 Institute for Biomedical Research (INBIOMED), Faculty of Medicine, University of Buenos Aires - CONICET (National Scientific and Technical Research Council), Buenos Aires, Argentina
2 Genotyping Section, DAC, CEMIC, Buenos Aires, Argentina

Rivera-Herrera et al. reported the analysis of CHEK2 c.1100delC in a population selected following the NCCN criteria, very well detailed in table 1. The MS is clearly written and thus, easy to follow.

Specific comments:

1. The actual nomenclature for this variant is of CHEK2 c.1100del.

2. It might be important to have the information of the ethnic origin of the probands analyzed since this pathogenic variant in common in Northern-European countries and to make a population conclusion it is critical.

3. The number of patients analyzed it is low based on the expected frequency in the northern countries that may have the highest, 0.5-1.16%, while it is expected based on the databases 100 times lower in Latin populations1. Although in Brazil it is reported 1.76%, based in 1 out 59 probands analyzed, a number still low to analyze a cohort of 131 patients and extrapolate to a population frequency.

4. The above comment does not deny the importance of the testing since the family diagnosis it is always very valuable for the counselling the relatives.

5. In methods it is very necessary to show the capacity to detect a positive mutation for CHEK2 c.1100del since a few reasons could account for a false negative result. The authors should include the DNA sequence profile for this positive control, in the case it was done.

6. A brief explanation of the method used for BRCA1/2, as the patients were selected for not
being a carrier of a mutation in those genes.

References

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
No

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Diagnostic laboratory, genes sequencing

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Reviewer Report 04 April 2019

https://doi.org/10.5256/f1000research.14514.r46435

© 2019 Muranen T. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Taru A. Muranen**
Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland

Rivera-Herrera et al. report a carefully designed study on the occurrence of a moderate-
penetrance breast cancer-susceptibility mutation CHEK2: c.1100delC. The paper is well written and the methods and results clearly articulated.

c.1100delC is a founder mutation enriched in certain Northern-European populations. The two-to threefold increased risk associated with the mutation and the relatively high population carrier frequency (0.5-1.5%) e.g. in the United States, United Kingdom, The Netherlands, Germany, and Finland has prompted the inclusion of the mutation in the panels used for genetic counselling. However, in countries, where the c.1100delC frequency is very low (less than 0.1%), testing for the mutation may not be cost-effective. On the other hand, since c.1100delC is a causal mutation with verified risk effect, independent of the genetic background or ethnicity, even in countries with admixed population and very low carrier frequency the positive carrier status is informative for the rare mutation carriers and their families.

The report of Rivera-Herrera et al. serves well in the building of an overall view of breast cancer risk mutations present in Hispanic populations and would thus deserve visibility in the scientific community. However, they should address the limitations of their study and report the genotyping conditions in more detail. There are two issues:

1. In genotyping, they should use a positive control, i.e. a DNA sample from a c.1100delC carrier, to ensure proper performance of the assay. Referring to conditions and assays used in previous studies is not enough, because the assay ought to be optimized on site. If the authors had included a positive control, they should indicate it in the text.
2. The authors should discuss the power of their analysis. Assuming underlying carrier frequency of 1.16% (as in Couch et al. 2017, JAMA Oncology) in Colombian breast cancer families, the probability of by chance not detecting any carrier in 131 probands would be 21.7%, which is rather high for a conclusion that the mutation is not present in the country. The authors refer to other studies in Latin-American countries and claim that the c.1100delC mutation is absent or has very low frequency. These studies are also quite small. Furthermore, in the Brazilian studies the mutation frequency in families appeared comparable to the frequency in Couch et al., and thus should not be referred to as very low.

References

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

**Are all the source data underlying the results available to ensure full reproducibility?**
No source data required

**Are the conclusions drawn adequately supported by the results?**
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Cancer genetics, breast cancer

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com